Uncover key drivers, emerging technologies, and competitive movements shaping the acquired autoimmune hemolytic anemia market from 2026–2035 with trusted insights from The Business Research Company
What is the expected shift in the Acquired Autoimmune Hemolytic Anemia Market’s size between 2026 and 2030?
The market size for acquired autoimmune hemolytic anemia has experienced substantial growth in recent years. This market is anticipated to expand from $2.14 billion in 2025 to $2.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. The historic growth can be attributed to several factors such as improved diagnosis of autoimmune diseases, the reliance on corticosteroid treatments, increased specialization in hospital hematology, a rise in malignancy-linked anemia cases, and the greater availability of diagnostic tests.
The market size for acquired autoimmune hemolytic anemia is anticipated to experience robust expansion over the coming years. It is projected to climb to $3.01 billion by 2030, with a compound annual growth rate (CAGR) of 7.1%. This growth during the forecast period can be attributed to increasing awareness of rare diseases, the adoption of biologic therapies, the integration of advanced diagnostics, heightened funding for hematology research, and the emergence of personalized treatment protocols. Significant trends expected during this period include the rising application of targeted immunosuppressive therapies, increased utilization of rituximab-based treatments, an expansion in hospital-based hematology care, greater adoption of improved diagnostic testing, and the broadening of rare disease treatment programs.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp
Which Drivers Are Shaping Strategic Decisions In The Acquired Autoimmune Hemolytic Anemia Market?
The expanding occurrence of autoimmune disorders is anticipated to stimulate the growth of the acquired autoimmune hemolytic anemia market in the future. Autoimmune disorders are characterized by the immune system mistakenly attacking the body’s own healthy cells and tissues, perceiving them as harmful invaders. The increasing incidence of autoimmune disorders is primarily linked to heightened environmental factors and changes in lifestyle that can disrupt immune system regulation. This rising prevalence of autoimmune disorders directly contributes to a higher incidence of acquired autoimmune hemolytic anemia, given that individuals with autoimmune conditions are more prone to developing secondary AIHA due to compromised immune system function. For instance, in 2023, data from the Gastro-Intestinal Epidemiology Consortium (CanGIEC), a national network of researchers and clinicians in Canada, indicated the prevalence of inflammatory bowel disease at an estimated 825 cases per 100,000 people. This prevalence is projected to grow by 2.44% annually, reaching 1,075 cases per 100,000 people by 2035. Therefore, the growing prevalence of autoimmune disorders will be a key driver for the expansion of the acquired autoimmune hemolytic anemia market.
What Segment Classifications Make Up The Acquired Autoimmune Hemolytic Anemia Market?
The acquired autoimmune hemolytic anemia market covered in this report is segmented –
1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test
2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Specialty Clinics, Research Institutions
Subsegments:
1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count
2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count
3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test
4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing
Which Competitive Trends Are Impacting The Structure Of The Acquired Autoimmune Hemolytic Anemia Market?
Leading companies in the autoimmune hemolytic anemia market are directing their efforts towards advances in targeted therapies, such as neonatal Fc receptor (FcRn) blockers. This focus aims to boost treatment effectiveness, improve maternal-fetal health outcomes, and offer more robust interventions for high-risk pregnancies complicated by severe hemolytic disease. An FcRn blocker is a therapeutic antibody crafted to suppress the neonatal Fc receptor, which is responsible for the recycling of immunoglobulin G (IgG) antibodies within the body. By doing so, it diminishes pathogenic antibody levels that lead to red blood cell destruction and hemolytic complications in both maternal and fetal populations. For example, in January 2025, Johnson & Johnson, a US-based pharmaceutical and healthcare company, obtained U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for nipocalimab. This designation is for its application in treating individuals at elevated risk for severe hemolytic disease of the fetus and newborn (HDFN). Nipocalimab functions by specifically blocking the neonatal Fc receptor (FcRn), thereby reducing maternal IgG antibody levels that cross the placenta and harm fetal red blood cells. This action consequently prevents severe hemolytic disease, lessens the requirement for intrauterine transfusions, and improves outcomes for at-risk pregnancies. Nipocalimab precisely targets FcRn-mediated IgG recycling while leaving other immune functions unaffected.
Which Major Firms Are Strengthening Their Position In The Acquired Autoimmune Hemolytic Anemia Market?
Major companies operating in the acquired autoimmune hemolytic anemia market are F. Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Novartis AG, Incyte Corporation, BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Johnson & Johnson, Merck KGaA, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, CSL Behring, Grifols S.A.
Access The Complete Report For Deeper Market Insights:
Which Region Shows The Strongest Potential For Future Expansion In The Acquired Autoimmune Hemolytic Anemia Market?
North America was the largest region in the acquired autoimmune hemolytic anemia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired autoimmune hemolytic anemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Acquired Autoimmune Hemolytic Anemia Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24132&type=smp
Browse Through More Reports Similar to the Global Acquired Autoimmune Hemolytic Anemia Market 2026, By The Business Research Company
Autoimmune Disease Diagnosis Market Report 2026
https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report
Autoimmune Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report
Anemia And Other Blood Disorder Drugs Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model